Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAR446597
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies
- Administration
- Ophthalmic, Intravitreal
01
Overview
SAR446597 is an investigational adeno-associated virus (AAV) gene therapy developed by Sanofi for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Administered as a one-time intravitreal injection, the therapy delivers a transgene encoding a modified version of human Complement Factor I (CFI), a key regulatory protease that downregulates the alternative complement pathway. By increasing local expression of CFI, SAR446597 aims to inhibit the overactive complement cascade that drives retinal pigment epithelium (RPE) cell death and lesion expansion in GA. The therapy is currently being evaluated in Phase 1/2 clinical trials to assess its safety, tolerability, and efficacy in slowing the progression of retinal atrophy.
- Other names
- tusamitamab-Sanofi-geographic atrophyAAV-CFI gene therapy
02
Targets
B. burgdorferi (Borrelia burgdorferi)C1S (Complement component 1s subcomponent serine protease)
Beyond the preview
Go deeper on SAR446597.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAR446597.